Search

Background: Proton pump inhibitors (PPIs) are usually prescribed to prevent gastrointestinal (GI) complications in patients receiving dual antiplatelet therapy (DAPT). This systematic review and meta-analysis aimed to explore the efficacy and safety of the concomitant use of PPIs with aspirin-clopidogrel DAPT in patients with Coronary heart disease (CHD).Method: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched from inception to August 2022 for eligible studies. The adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the clinical outcomes. Subgroup analysis was conducted according to different PPI subtypes, populations, follow-up times and study types. This study was registered on PROSPERO (CRD42022332195).Results: A total of 173,508 patients from 18 studies [2 randomized controlled trials (RCTs), 3 post hoc analyses of RCTs, and 13 cohort studies] were included in this study. Pooled data revealed that coadministration of PPIs significantly increased the risk of major adverse cardiovascular events (MACEs) (HR = 1.15, 95% CI = 1.06–1.26, p = .001) and reduced the risk of gastrointestinal (GI) complications (HR = 0.44, 95% CI = 0.30–0.64, p < .0001). Subgroup analysis results showed that the esomeprazole users and patients with coronary stenting in the PPI group were associated with an increased risk of MACEs compared with the non-PPI group. The occurrence of MACEs in PPI users was more common than that in non-PPI users in long-term follow-up (≥12 months) studies and in the observational studies. There was no significant differences in the incidences of net clinical adverse events (NACEs), all-cause mortality, or cardiac death between the two groups.Conclusion: In patients with CHD, the concomitant use of PPIs with aspirin and clopidogrel was associated with a reduced risk of GI complications but could increase the rates of MACEs (particularly in patients receiving esomeprazole or with coronary stenting). There was no clear evidence of an association between PPI use and NACEs, all-cause mortality, or cardiac death. The results could have been affected by the follow-up time and study type. Further large-scale RCTs with long-term follow-up are needed.

Additional file 2: Table S1. Computational alanine scanning on the complex of extracellular domains 1-3 of hCD22 and HIB22 scFv. Table S2. Non-covalent bonds involved in antigen-scFv interaction. Figure S1. The expression of CD22 on cell lines and B-ALL patient samples. Figure S2. Pathologic analysis,cytokines release in vivo and CAR-T construct and cell lines used in xenograft models. Figure S3. Aplasia of B cells, CD19 and CD22 expression in leukemia blasts at pretreatment stage in patients, and T cells subtypes during treatment

Additional file 1. Additional methods.

Supplemental Material, sj-pdf-1-jfi-10.1177_0192513X211042843 for Interparental Conflict and Chinese Children’s Social Development by Fengjiao Xu, Xinyi Chen, Haiyan Xing and Hongmei Wang in Journal of Family Issues

Additional file 1. Supplementary material and methods. Fig. S1. Affinity of PO-6 and mPO-6 to different leukemia cells. Fig.S2. The TEM image of mPO-6. Fig. S3. Confocal microscopy observation of PO-6 binding with MOLM-13 cells. Fig. S4. mPO-6 inhibited the antibodies binding to CD123. Fig. S5. Affinity of mPO-6 to the AML blasts. Fig. S6. CD123 expression on GFP+ cells in BM of AE & CKITD816V mice. Fig. S7. Therapeutic efficacy of Ara-C or HHT in AE & CKITD816V mice. Fig. S8. The fluorescent representative imaging of main organs at designated time points after mPO-6-FITC injection in healthy mice. Fig. S9. Acute toxicity evaluation of mPO-6 in healthy mice. Table S1. Human and mouse CD123 alignment of the extracellular amino acid sequences.

Background—The active monomer Verbascum glycosides in Cistanche tubulosa has good development prospects in terms of neuroprotection and delaying neurodegenerative diseases, and it has become one of the research hot spots. To investigate the effect of verbascoside (OC1) on the expression of phosphorylated protein in the protective effect of AD cell model by TMT labeling and phosphorylation enrichment technique and high-resolution liquid chromatography-mass spectrometry quantitative proteomics research strategy. Methods—The normal control group, the model group Aβ1-42(10μmol/L) group and the OC1(10μg/ml) administration group were set. (1)protein extraction quality control. (2)TMT mark. (3)HPLC classification and modification enrichment. (4)Analysis of mass spectrometry by liquid chromatography-mass spectrometry. (5)Analysis of bioinformatics results. (6)Western Blotting was used to detect the expression levels of p-CaMKII(Thr286), p-Synapsin1(Ser603)/Synapsin1, Synaptophysin and Synaptotagmin-1 protein. Results—The study finally identified 9020 phosphorylation sites on 3227 proteins, of which 8635 sites of 3134 proteins contained quantitative information. Screening of differential sites follows the following criteria: 1.2 times the change threshold and CV value < 0.1. Based on the above data and standards, we performed a systematic bioinformatics analysis of proteins containing quantitative information sites. Western Blotting results showed that Verbascoside could promote the expression of p-CaMKII (Thr286), p-Synapsin (Ser603)/Synapsin, Synaptophysin and Synaptotagmin-1 protein. Conclusions—Verbascoside(OC1) can increase the expression of phosphorylated protein in AD cell model, which provides a basis for further study on the molecular mechanism of verbascoside promoting neurotransmitter release.